Skip to main content
. Author manuscript; available in PMC: 2020 Feb 7.
Published in final edited form as: Cell. 2019 Feb 7;176(4):687–701.e5. doi: 10.1016/j.cell.2018.12.004

Figure 5. Small molecule screen identifies NPYLR7 agonists with in vivo activity.

Figure 5.

(A) Schematic of high-throughput small molecule screen for NPYLR7 agonists.

(B) 24 confirmed in vitro hits tested for in vivo activity using the miniport olfactometer (median with interquartile range, n = 4 – 116, 15 - 25 females/trial). Compounds are indicated at the top of the figure with identifier number in a circle. Groups in green are significantly different compared to saline meal control (Kruskal-Wallis test with Dunn’s multiple comparison p<0.05).

(c) In vivo dose-response tests of 6 primary hits in the miniport olfactometer (median with interquartile range, n=4 – 6, 15 - 25 females/trial). Data from inactive compound 8 are replotted in all 6 panels.

(D-E) In vitro response profile of NPYLR7-activating compounds against all predicted peptide receptors in the L3 (D) and L5 (E) annotation of the Ae. aegypti genome.

(F) In vitro response profile of NPYLR7-activating compounds against human NPY receptors.